<p>隨着美國市場在不斷上升的國債收益率和對聯邦儲備政策的不確定性中航行，投資者密切關注內部人士活動，作為公司增長前景信心的潛在指標。在這種氣候下，擁有高內部人士持股的股票可能表明管理層與股東之間的強大一致性，這在市場條件波動時尤其吸引人。</p>
<h3>美國內部人士持股比例高的十大成長公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部人士持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>超微電腦 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.1%</td>
<td>59%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Prairie Operating (PROP)</td>
<td>32.2%</td>
<td>100%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>101.1%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>28.9%</td>
<td>46.2%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.5%</td>
<td>43.6%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>135.3%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.5%</td>
<td>28.9%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們內部人士持股比例高的快速成長美國公司篩選器中的 209 只股票的完整列表。</p>
<p>我們將查看篩選工具中的一些最佳選擇。</p>
<h2>CapsoVision (CV)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> CapsoVision, Inc. 是一家醫療技術公司，製造和銷售用於胃腸系統成像的內窺鏡視頻成像設備，市值為 2.9183 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其膠囊內窺鏡部門，金額為 1309 萬美元。</p>
<p><strong>內部人士持股：</strong> 24.8%</p>
<p><strong>收益增長預測：</strong> 每年 56.4%。</p>
<p>CapsoVision 正在通過顯著的內部人士持股推進其增長戰略，專注於創新的診斷技術。該公司最近向 FDA 提交了 AI 輔助模塊的 510(k) 申請，並有可能獲得胰腺癌檢測的突破性設備認證，突顯其擴展產品線的承諾。儘管在 2025 年第三季度淨虧損為 792 萬美元，但收入同比增長 16.3%，預計未來三年內盈利能力將實現，因為收入預測顯著超過市場。</p>
<ul>
<li>在這裏深入瞭解 CapsoVision 的全面分析和未來增長報告。</li>
<li>我們的估值報告顯示 CapsoVision 可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2d63d9fe-0251-4c55-a3e0-3a9d23c7af68/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2d63d9fe-0251-4c55-a3e0-3a9d23c7af68/chart/ownership-breakdown"/></p>
<p>截至 2026 年 1 月的 CV 持股分佈</p>
<h2>Harrow (HROW)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Harrow, Inc. 是一家眼科製藥公司，專注於發現、開發和商業化眼科藥品，市值約為 17.7 億美元。</p>
<p><strong>運營：</strong> Harrow 通過其品牌部門產生收入，金額為 1.6797 億美元，以及其配方部門，貢獻 8207 萬美元。</p>
<p><strong>內部人士持股：</strong> 16.2%</p>
<p><strong>收益增長預測：</strong> 每年 45.4%。</p>
<p>Harrow 正在經歷強勁增長，預計其收入將以每年 26.8% 的速度增長，超過美國市場。該公司報告 2025 年第三季度收入為 7164 萬美元，較去年同期的 4926 萬美元有所增長，並實現淨收入為 102 萬美元，而之前則是虧損。儘管交易價格顯著低於估計的公允價值，並且缺乏最近的內部人士買賣數據，分析師預計股價將上漲 47.4%。</p>
<ul>
<li>在此增長報告中解鎖我們對 Harrow 股票分析的全面見解。</li>
<li>根據我們的估值報告，Harrow 的股價可能偏低。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aab17550-e396-4149-bdca-440135e903d3/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aab17550-e396-4149-bdca-440135e903d3/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 1 月的 HROW 收益和收入增長</p>
<h2>Upstart Holdings (UPST)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Upstart Holdings, Inc. 在美國運營一個基於雲的 AI 貸款平台，市值約為 46.8 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其個人貸款部門，產生 8688.2 萬美元。</p>
<p><strong>內部人士持股：</strong> 12.6%</p>
<p><strong>收益增長預測：</strong> 每年 68.9%。</p>
<p>Upstart Holdings 在過去三個月內經歷了大量內部人士買入，表明對其增長軌跡的信心。該公司最近實現盈利，報告 2025 年第三季度淨收入為 3181 萬美元，而之前則是虧損。預計收益將顯著增長，年增長率為 68.87%，超過美國市場。儘管收入增長預測低於收益，但 Upstart 與 MyPoint 信用合作社和 Tech CU 等金融機構的合作增強了其市場存在感和擴展潛力。</p>
<ul>
<li>在這裏通過我們的全面分析師估計報告深入瞭解 Upstart Holdings 的複雜性。</li>
<li>我們的全面估值報告提出 Upstart Holdings 的定價可能高於其財務狀況所能證明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ce1058c-f6d8-4269-943f-f42e0cef9faf/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ce1058c-f6d8-4269-943f-f42e0cef9faf/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 1 月的 UPST 收益和收入增長</p>
<h2>抓住機會</h2>
<ul>
<li>點擊這裏深入瞭解 209 家內部人士持股比例高的快速成長美國公司的全貌。</li>
<li>對其他選擇感到好奇？AI 即將改變醫療保健。這 110 只股票正在從早期診斷到藥物發現等各個方面進行工作。最重要的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有引用的預測收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

超微電腦

HROW

UPST

PROP

<p>隨着美國市場面臨不斷上升的國債收益率和聯邦儲備的不確定性，內部人士活動被密切關注，作為公司增長信心的指標。內部持股比例高的股票，如超微電腦（Super Micro Computer，SMCI）和 Prairie Operating（PROP），因其潛力而受到關注。像 CapsoVision 和 Harrow 這樣的公司顯示出有希望的盈利增長預測，內部持股表明管理層的強大一致性。Upstart Holdings 經歷了顯著的內部人士買入，表明對其增長軌跡的信心。文章強調了在波動市場條件下，內部持股的重要性</p>

<p>As U.S. markets navigate a landscape of rising Treasury yields and uncertainty surrounding Federal Reserve policies, investors are keenly observing insider activities as a potential indicator of confidence in company growth prospects. In this climate, stocks with high insider ownership may signal strong alignment between management and shareholders, which can be particularly appealing when market conditions are volatile.</p>
<div class="lb-trans"><p>隨着美國市場在不斷上升的國債收益率和對聯邦儲備政策的不確定性中航行，投資者密切關注內部人士活動，作為公司增長前景信心的潛在指標。在這種氣候下，擁有高內部人士持股的股票可能表明管理層與股東之間的強大一致性，這在市場條件波動時尤其吸引人。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美國內部人士持股比例高的十大成長公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Super Micro Computer (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.1%</td>
<td>59%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Prairie Operating (PROP)</td>
<td>32.2%</td>
<td>100%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>101.1%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>28.9%</td>
<td>46.2%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.5%</td>
<td>43.6%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>135.3%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.5%</td>
<td>28.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部人士持股</strong></td>
<td><strong>收益增長</strong></td>
</tr>
<tr>
<td>超微電腦 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.1%</td>
<td>59%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Prairie Operating (PROP)</td>
<td>32.2%</td>
<td>100%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>101.1%</td>
</tr>
<tr>
<td>GBank Financial Holdings (GBFH)</td>
<td>28.9%</td>
<td>46.2%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.5%</td>
<td>43.6%</td>
</tr>
<tr>
<td>Bitdeer Technologies Group (BTDR)</td>
<td>33.4%</td>
<td>135.3%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>10.5%</td>
<td>28.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 209 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們內部人士持股比例高的快速成長美國公司篩選器中的 209 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看篩選工具中的一些最佳選擇。</p>
</div><h2>CapsoVision (CV)</h2>
<div class="lb-trans"><h2>CapsoVision (CV)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> CapsoVision, Inc. is a medical technology company that manufactures and markets endoscopic video imaging devices for gastrointestinal system imaging, with a market cap of $291.83 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> CapsoVision, Inc. 是一家醫療技術公司，製造和銷售用於胃腸系統成像的內窺鏡視頻成像設備，市值為 2.9183 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily generated from its Capsule Endoscopy segment, amounting to $13.09 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其膠囊內窺鏡部門，金額為 1309 萬美元。</p>
</div><p><strong>Insider Ownership:</strong> 24.8%</p>
<div class="lb-trans"><p><strong>內部人士持股：</strong> 24.8%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 56.4% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 56.4%。</p>
</div><p>CapsoVision is advancing its growth strategy with significant insider ownership, focusing on innovative diagnostic technologies. The company's recent 510(k) submission to the FDA for an AI-assisted module and potential Breakthrough Device Designation for pancreatic cancer detection highlight its commitment to expanding its product line. Despite a net loss of US$7.92 million in Q3 2025, revenue grew by 16.3% year-over-year, with future profitability expected within three years as revenue forecasts outpace the market significantly.</p>
<div class="lb-trans"><p>CapsoVision 正在通過顯著的內部人士持股推進其增長戰略，專注於創新的診斷技術。該公司最近向 FDA 提交了 AI 輔助模塊的 510(k) 申請，並有可能獲得胰腺癌檢測的突破性設備認證，突顯其擴展產品線的承諾。儘管在 2025 年第三季度淨虧損為 792 萬美元，但收入同比增長 16.3%，預計未來三年內盈利能力將實現，因為收入預測顯著超過市場。</p>
</div><ul>
<li>Delve into the full analysis future growth report here for a deeper understanding of CapsoVision.</li>
<li>Our valuation report here indicates CapsoVision may be overvalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解 CapsoVision 的全面分析和未來增長報告。</li>
<li>我們的估值報告顯示 CapsoVision 可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2d63d9fe-0251-4c55-a3e0-3a9d23c7af68/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/2d63d9fe-0251-4c55-a3e0-3a9d23c7af68/chart/ownership-breakdown"/></p>
<p>CV Ownership Breakdown as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月的 CV 持股分佈</p>
</div><h2>Harrow (HROW)</h2>
<div class="lb-trans"><h2>Harrow (HROW)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Harrow, Inc. is an eyecare pharmaceutical company focused on discovering, developing, and commercializing ophthalmic pharmaceutical products with a market cap of approximately $1.77 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Harrow, Inc. 是一家眼科製藥公司，專注於發現、開發和商業化眼科藥品，市值約為 17.7 億美元。</p>
</div><p><strong>Operations:</strong> Harrow generates revenue through its Branded segment, which accounts for $167.97 million, and its Compounding segment, contributing $82.07 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> Harrow 通過其品牌部門產生收入，金額為 1.6797 億美元，以及其配方部門，貢獻 8207 萬美元。</p>
</div><p><strong>Insider Ownership:</strong> 16.2%</p>
<div class="lb-trans"><p><strong>內部人士持股：</strong> 16.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 45.4% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 45.4%。</p>
</div><p>Harrow is experiencing strong growth, with its revenue forecasted to grow at 26.8% per year, outpacing the US market. The company reported Q3 2025 revenue of US$71.64 million, up from US$49.26 million a year ago, and achieved net income of US$1.02 million compared to a prior loss. Despite trading significantly below estimated fair value and lacking recent insider buying or selling data, analysts expect a stock price increase of 47.4%.</p>
<div class="lb-trans"><p>Harrow 正在經歷強勁增長，預計其收入將以每年 26.8% 的速度增長，超過美國市場。該公司報告 2025 年第三季度收入為 7164 萬美元，較去年同期的 4926 萬美元有所增長，並實現淨收入為 102 萬美元，而之前則是虧損。儘管交易價格顯著低於估計的公允價值，並且缺乏最近的內部人士買賣數據，分析師預計股價將上漲 47.4%。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Harrow stock in this growth report.</li>
<li>According our valuation report, there's an indication that Harrow's share price might be on the cheaper side.</li>
</ul>
<div class="lb-trans"><ul>
<li>在此增長報告中解鎖我們對 Harrow 股票分析的全面見解。</li>
<li>根據我們的估值報告，Harrow 的股價可能偏低。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/aab17550-e396-4149-bdca-440135e903d3/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/aab17550-e396-4149-bdca-440135e903d3/chart/earnings-and-revenue-growth"/></p>
<p>HROW Earnings and Revenue Growth as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月的 HROW 收益和收入增長</p>
</div><h2>Upstart Holdings (UPST)</h2>
<div class="lb-trans"><h2>Upstart Holdings (UPST)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Upstart Holdings, Inc. operates a cloud-based AI lending platform in the United States and has a market cap of approximately $4.68 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Upstart Holdings, Inc. 在美國運營一個基於雲的 AI 貸款平台，市值約為 46.8 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its personal lending segment, which generated $868.82 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其個人貸款部門，產生 8688.2 萬美元。</p>
</div><p><strong>Insider Ownership:</strong> 12.6%</p>
<div class="lb-trans"><p><strong>內部人士持股：</strong> 12.6%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 68.9% p.a.</p>
<div class="lb-trans"><p><strong>收益增長預測：</strong> 每年 68.9%。</p>
</div><p>Upstart Holdings has seen substantial insider buying over the past three months, indicating confidence in its growth trajectory. The company recently became profitable, reporting a Q3 2025 net income of US$31.81 million compared to a prior loss. Earnings are forecast to grow significantly at 68.87% per year, outpacing the US market. Despite revenue growth forecasts being slower than earnings, Upstart's partnerships with financial institutions like MyPoint Credit Union and Tech CU enhance its market presence and potential for expansion.</p>
<div class="lb-trans"><p>Upstart Holdings 在過去三個月內經歷了大量內部人士買入，表明對其增長軌跡的信心。該公司最近實現盈利，報告 2025 年第三季度淨收入為 3181 萬美元，而之前則是虧損。預計收益將顯著增長，年增長率為 68.87%，超過美國市場。儘管收入增長預測低於收益，但 Upstart 與 MyPoint 信用合作社和 Tech CU 等金融機構的合作增強了其市場存在感和擴展潛力。</p>
</div><ul>
<li>Navigate through the intricacies of Upstart Holdings with our comprehensive analyst estimates report here.</li>
<li>Our comprehensive valuation report raises the possibility that Upstart Holdings is priced higher than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏通過我們的全面分析師估計報告深入瞭解 Upstart Holdings 的複雜性。</li>
<li>我們的全面估值報告提出 Upstart Holdings 的定價可能高於其財務狀況所能證明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2ce1058c-f6d8-4269-943f-f42e0cef9faf/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/2ce1058c-f6d8-4269-943f-f42e0cef9faf/chart/earnings-and-revenue-growth"/></p>
<p>UPST Earnings and Revenue Growth as at Jan 2026</p>
<div class="lb-trans"><p>截至 2026 年 1 月的 UPST 收益和收入增長</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Gain an insight into the universe of 209 Fast Growing US Companies With High Insider Ownership by clicking here.</li>
<li>Curious About Other Options? AI is about to change healthcare. These 110 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 209 家內部人士持股比例高的快速成長美國公司的全貌。</li>
<li>對其他選擇感到好奇？AI 即將改變醫療保健。這 110 只股票正在從早期診斷到藥物發現等各個方面進行工作。最重要的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有引用的預測收入和盈利增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

Insider-Owned Growth Stocks Poised For Success In January 2026

- 投資者關注美國高管持股的公司以判斷增長潛力。  
- 提供美國高管持股前 10 名增長公司及其盈利增長率。  
- 提及 CapsoVision、Harrow 和 Upstart 的財務表現及未來增長預測。

內部人士持有的成長型股票在 2026 年 1 月有望取得成功